2.85
Schlusskurs vom Vortag:
$3.06
Offen:
$3.1
24-Stunden-Volumen:
3.34M
Relative Volume:
1.51
Marktkapitalisierung:
$384.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.47M
KGV:
-5.00
EPS:
-0.57
Netto-Cashflow:
$-124.27M
1W Leistung:
-11.49%
1M Leistung:
+4.01%
6M Leistung:
+261.13%
1J Leistung:
+83.87%
Prokidney Corp Stock (PROK) Company Profile
Firmenname
Prokidney Corp
Sektor
Branche
Telefon
336-999-7028
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Vergleichen Sie PROK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
PROK
Prokidney Corp
|
2.85 | 416.09M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-30 | Eingeleitet | JP Morgan | Neutral |
| 2024-09-10 | Eingeleitet | Guggenheim | Buy |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-07-25 | Eingeleitet | BTIG Research | Buy |
| 2022-12-21 | Eingeleitet | Jefferies | Buy |
| 2022-11-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Eingeleitet | UBS | Buy |
| 2022-10-14 | Eingeleitet | Citigroup | Buy |
| 2022-09-23 | Eingeleitet | BofA Securities | Buy |
| 2022-09-02 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Prokidney Corp Aktie (PROK) Neueste Nachrichten
Will ProKidney Corp. stock beat EPS estimatesQuarterly Profit Summary & Reliable Trade Execution Plans - newser.com
Is now a turning point for ProKidney Corp.Quarterly Performance Summary & AI Powered Buy and Sell Recommendations - newser.com
Is ProKidney Corp. stock poised for growthWeekly Trade Summary & Daily Volume Surge Signals - newser.com
Automated trading signals detected on ProKidney Corp.Weekly Trend Recap & AI Driven Stock Movement Reports - newser.com
What candlestick patterns are forming on ProKidney Corp.2025 Performance Recap & Entry Point Strategy Guides - newser.com
Heatmap analysis for ProKidney Corp. and competitorsJuly 2025 Fed Impact & Scalable Portfolio Growth Methods - newser.com
What valuation multiples suggest for ProKidney Corp. stockJuly 2025 Catalysts & Weekly Momentum Picks - newser.com
What to expect from ProKidney Corp. in the next 30 daysPortfolio Profit Report & Trade Opportunity Analysis - newser.com
Visual analytics tools that track ProKidney Corp. performancePortfolio Update Report & Weekly Setup with High ROI Potential - newser.com
Will ProKidney Corp. stock recover faster than peersShare Buyback & Verified Momentum Stock Watchlist - newser.com
Will ProKidney Corp. stock go up soonRisk Management & Long-Term Safe Investment Ideas - newser.com
How ProKidney Corp. stock performs in stagflationSwing Trade & Community Trade Idea Sharing - newser.com
What technical charts say about ProKidney Corp. stockJuly 2025 EndofMonth & Growth Oriented Trading Recommendations - newser.com
ProKidney (NASDAQ:PROK) Shares Down 8.2%Should You Sell? - MarketBeat
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference - The Manila Times
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - Investing News Network
Guidance Update: Can ProKidney Corp. stock weather global recessionJuly 2025 Institutional & Daily Risk Controlled Trade Plans - fcp.pa.gov.br
Finanzdaten der Prokidney Corp-Aktie (PROK)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):